These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2918 related articles for article (PubMed ID: 20107219)
41. Alzheimer's disease neuropathology. Current status of interpretation of lesion development. Wisniewski HM; Wegiel J Ann N Y Acad Sci; 1992 Dec; 673():270-84. PubMed ID: 1485725 [No Abstract] [Full Text] [Related]
42. Amyloid protein and Alzheimer's disease. Selkoe DJ Sci Am; 1991 Nov; 265(5):68-71, 74-6, 78. PubMed ID: 1785042 [No Abstract] [Full Text] [Related]
43. Heparan sulfates demonstrate potential for Alzheimer’s disease therapy. Hill R Future Med Chem; 2013 Jul; 5(11):1190. PubMed ID: 24020082 [No Abstract] [Full Text] [Related]
44. Mitochondrial dysfunction: different routes to Alzheimer's disease therapy. Picone P; Nuzzo D; Caruana L; Scafidi V; Di Carlo M Oxid Med Cell Longev; 2014; 2014():780179. PubMed ID: 25221640 [TBL] [Abstract][Full Text] [Related]
45. Strategic Approaches to Target the Enzymes using Natural Compounds for the Management of Alzheimer's Disease: A Review. Ahmad SS; Younis K; Philippe J; Aschner M; Khan H CNS Neurol Disord Drug Targets; 2022; 21(7):610-620. PubMed ID: 34382514 [TBL] [Abstract][Full Text] [Related]
47. [Recent advances in Alzheimer's disease]. Morishima-Kawashima M; Ihara Y Seikagaku; 2001 Nov; 73(11):1297-307. PubMed ID: 11831025 [No Abstract] [Full Text] [Related]
48. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Yanagisawa K; Odaka A; Suzuki N; Ihara Y Nat Med; 1995 Oct; 1(10):1062-6. PubMed ID: 7489364 [TBL] [Abstract][Full Text] [Related]
49. [Alzheimer's disease--the molecular biological mechanism and the therapeutic drug design]. Nabeshima T; Takeda M Nihon Yakurigaku Zasshi; 1996 Sep; 108(3):132-4. PubMed ID: 9091440 [No Abstract] [Full Text] [Related]
50. Role of amyloid beta-protein in Alzheimer's disease. Barker A Lancet; 1992 Oct; 340(8823):850-1. PubMed ID: 1357268 [No Abstract] [Full Text] [Related]
51. Structural basis of β-amyloid-dependent synaptic dysfunctions. Haupt C; Leppert J; Rönicke R; Meinhardt J; Yadav JK; Ramachandran R; Ohlenschläger O; Reymann KG; Görlach M; Fändrich M Angew Chem Int Ed Engl; 2012 Feb; 51(7):1576-9. PubMed ID: 22234970 [No Abstract] [Full Text] [Related]
52. Alzheimer's disease: A prion protein connection. Cisse M; Mucke L Nature; 2009 Feb; 457(7233):1090-1. PubMed ID: 19242462 [No Abstract] [Full Text] [Related]
53. [Morphology and neurotoxicity of newly identified spherical beta-amyloid aggregates, 'amylospheroid', aiming at elucidation of the neurodegenerative cascades in Alzheimer's disease]. Hoshi M Seikagaku; 2004 Jul; 76(7):631-9. PubMed ID: 15346899 [No Abstract] [Full Text] [Related]
54. Drug trapping and delivery for Alzheimer's diagnosis. Jalil MA; Kamoldilok S; Saktioto T; Ong CT; Yupapin PP Artif Cells Blood Substit Immobil Biotechnol; 2012 Oct; 40(5):303-8. PubMed ID: 22384850 [TBL] [Abstract][Full Text] [Related]
55. [New approaches for the development of anti-Alzheimer's disease drugs based on the cholinergic hypothesis and amyloid hypothesis]. Sugimoto H Nihon Yakurigaku Zasshi; 2008 May; 131(5):338-40. PubMed ID: 18480562 [No Abstract] [Full Text] [Related]
56. N-terminus truncated beta-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease. Geddes JW; Tekirian TL; Mattson MP Neurobiol Aging; 1999; 20(1):75-9; discussion 87. PubMed ID: 10466897 [No Abstract] [Full Text] [Related]
57. Neurodegeneration. Potential Alzheimer's drug spurs protein recycling. Garber K Science; 2014 Apr; 344(6182):351. PubMed ID: 24763565 [No Abstract] [Full Text] [Related]
58. Oxidative stress in Alzheimer's disease. Smith MA; Rottkamp CA; Nunomura A; Raina AK; Perry G Biochim Biophys Acta; 2000 Jul; 1502(1):139-44. PubMed ID: 10899439 [TBL] [Abstract][Full Text] [Related]
59. Recent Trends in the Management of Alzheimer's Disease: Current Therapeutic Options and Drug Repurposing Approaches. Singh RK Curr Neuropharmacol; 2020; 18(9):868-882. PubMed ID: 31989900 [TBL] [Abstract][Full Text] [Related]
60. Oligomerizaiton and fibril asssembly of the amyloid-beta protein. Roher AE; Baudry J; Chaney MO; Kuo YM; Stine WB; Emmerling MR Biochim Biophys Acta; 2000 Jul; 1502(1):31-43. PubMed ID: 10899429 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]